Completed
PHASE4
INTERVENTIONAL
NCT02883595
Efficacy of Thymosin Alpha 1 on Improving Monocyte Function for Sepsis
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The purpose of this study is to determine whether thymosin alpha 1 is effective on improving monocyte function and has the desired pharmacologic activity for sepsis
Detailed Description
Part 1: To observe the function of thymosin alpha 1 in sepsis patients via improving phagocytosis, bacteria eradication and antigen-presenting on monocyte Part 2: Pharmacokinetics of thymosin alpha 1 for sepsis
Interventions
Name:
thymosin alpha 1
Type:
DRUG
Description:
Subcutaneous injections of 1.6 mg thymosin alpha 1 twice per day for seven days, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.
Name:
Placebo
Type:
OTHER
Description:
Subcutaneous injections of placebo (saline) twice per day for seven days
Primary Outcomes
Measure:
Ta 1 improving immune function of monocyte for sepsis, used by flow cytometric to measure phagocytosis(CD11b, CD64), antigen presenting(HLA-DR, CD86 and PD-L1), and apoptosis(active caspase 3) on monocyte,
TimeFrame:
28days
Description:
Phagocytosis was measured by expression of monocyte surface antigen CD64 and CD11b, as well as pHrodo™ BioParticles® Phagocytosis Kits to assessing phagocytic activity on monocyte; antigen presenting was measured by HLA-DR, costimulatory molecule CD86 and inhibitory molecule PD-L1 on monocyte; apoptosis was measured by active caspase 3 on monocyte
Trial Information
NCT ID
NCT02883595
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE4
Sponsor
Sun Yat-sen University
Last Updated
December 15, 2025